No survival benefit with androgen suppression: study

In a retrospective cohort study of 15,000 newly diagnosed men, the researchers found no significant differences in risk of all-cause mortality, prostate cancer-specific mortality or cardiovascular mortality between those receiving PADT and those not receiving it.

They found a slightly reduced risk of death in men at high risk of cancer progression and a slightly raised risk of death among men with low risk disease.

Adverse effects of the therapy included cognitive impairment and diabetes.

J Clin Oncology 2014; online